Serving hundreds of leading biopharmaceutical companies globally:

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,479,496

« Back to Dashboard

Which drugs does patent 6,479,496 protect, and when does it expire?

Patent 6,479,496 protects RANEXA and is included in one NDA.

This patent has ninety-eight patent family members in twenty-nine countries.

Summary for Patent: 6,479,496

Title:	Methods for treating angina with ranolazine
Abstract:	A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
Inventor(s):	Wolff; Andrew A. (San Francisco, CA)
Assignee:	CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:	09/520,932
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,479,496
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,479,496
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 6,479,496

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead	RANEXA	ranolazine	TABLET, EXTENDED RELEASE;ORAL	021526-001	Feb 12, 2007	AB	RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE	➤ Sign Up
Gilead	RANEXA	ranolazine	TABLET, EXTENDED RELEASE;ORAL	021526-002	Jan 27, 2006	AB	RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,479,496

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	022085	➤ Sign Up
Argentina	052921	➤ Sign Up
Argentina	053440	➤ Sign Up
Austria	217794	➤ Sign Up
Austria	285774	➤ Sign Up
Australia	2001240092	➤ Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.